1. Stem Cells and Regenerative Medicine
Download icon

Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes

  1. Diego Balboa  Is a corresponding author
  2. Jonna Saarimäki-Vire
  3. Daniel Borshagovski
  4. Mantas Survila
  5. Päivi Lindholm
  6. Emilia Galli
  7. Solja Eurola
  8. Jarkko Ustinov
  9. Heli Grym
  10. Hanna Huopio
  11. Juha Partanen
  12. Kirmo Wartiovaara
  13. Timo Otonkoski  Is a corresponding author
  1. University of Helsinki, Finland
  2. University of Eastern Finland, Finland
Research Article
  • Cited 21
  • Views 4,165
  • Annotations
Cite this article as: eLife 2018;7:e38519 doi: 10.7554/eLife.38519

Abstract

Insulin gene mutations are a leading cause of neonatal diabetes. They can lead to proinsulin misfolding and its retention in endoplasmic reticulum (ER). This results in increased ER-stress suggested to trigger beta-cell apoptosis. In humans, the mechanisms underlying beta-cell failure remain unclear. Here we show that misfolded proinsulin impairs developing beta-cell proliferation without increasing apoptosis. We generated induced pluripotent stem cells (iPSCs) from people carrying insulin (INS) mutations, engineered isogenic CRISPR-Cas9 mutation-corrected lines and differentiated them to beta-like cells. Single-cell RNA-sequencing analysis showed increased ER-stress and reduced proliferation in INS-mutant beta-like cells compared with corrected controls. Upon transplantation into mice, INS-mutant grafts presented reduced insulin secretion and aggravated ER-stress. Cell size, mTORC1 signaling, and respiratory chain subunits expression were all reduced in INS-mutant beta-like cells, yet apoptosis was not increased at any stage. Our results demonstrate that neonatal diabetes-associated INS-mutations lead to defective beta-cell mass expansion, contributing to diabetes development.

Article and author information

Author details

  1. Diego Balboa

    Molecular Neurology Research Program Unit, University of Helsinki, Helsinki, Finland
    For correspondence
    diego.balboa@helsinki.fi
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4784-5452

  2. Jonna Saarimäki-Vire

    Molecular Neurology Research Program Unit, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  3. Daniel Borshagovski

    Department of Biosciences, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  4. Mantas Survila

    Department of Biosciences, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  5. Päivi Lindholm

    Institute of Biotechnology, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3022-5035

  6. Emilia Galli

    Institute of Biotechnology, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7419-611X

  7. Solja Eurola

    Molecular Neurology Research Program Unit, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  8. Jarkko Ustinov

    Molecular Neurology Research Program Unit, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  9. Heli Grym

    Molecular Neurology Research Program Unit, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  10. Hanna Huopio

    University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.

  11. Juha Partanen

    Department of Biosciences, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  12. Kirmo Wartiovaara

    Molecular Neurology Research Program Unit, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.

  13. Timo Otonkoski

    Molecular Neurology Research Program, University of Helsinki, Helsinki, Finland
    For correspondence
    timo.otonkoski@helsinki.fi
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9190-2496

Funding

Suomen Akatemia

  • Timo Otonkoski

Sigrid Juselius Foundation

  • Timo Otonkoski

Novo Nordisk Foundation

  • Timo Otonkoski

EU 7FP Integrated project BETACURE

  • Timo Otonkoski

Diabetes Research Foundation

  • Timo Otonkoski

Diabetes Wellness Foundation

  • Diego Balboa
  • Jonna Saarimäki-Vire

Biomedicum Helsinki Foundation

  • Diego Balboa

INNODIA

  • Timo Otonkoski

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal care and experiments were conducted as approved by the National Animal Experiment Board in Finland (ESAVI/9978/04.10.07/2014).

Human subjects: The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (no. 423/13/03/00/08) approved the patient informed consent for the derivation of the hiPSC lines used in this study: HEL71.4 and HEL107.2.

Reviewing Editor

  1. Anna L Gloyn, University of Oxford, United Kingdom

Publication history

  1. Received: May 20, 2018
  2. Accepted: November 6, 2018
  3. Accepted Manuscript published: November 9, 2018 (version 1)
  4. Version of Record published: December 14, 2018 (version 2)

Copyright

© 2018, Balboa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,165
    Page views
  • 686
    Downloads
  • 21
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Categories and tags

Research organism

Further reading

    1. Cell Biology
    2. Genetics and Genomics

    Inhibition of mTORC1 by ER stress impairs neonatal β-cell expansion and predisposes to diabetes in the Akita mouse

    Yael Riahi et al.
    Research Article Updated

    Unresolved ER stress followed by cell death is recognized as the main cause of a multitude of pathologies including neonatal diabetes. A systematic analysis of the mechanisms of β-cell loss and dysfunction in Akita mice, in which a mutation in the proinsulin gene causes a severe form of permanent neonatal diabetes, showed no increase in β-cell apoptosis throughout life. Surprisingly, we found that the main mechanism leading to β-cell dysfunction is marked impairment of β-cell growth during the early postnatal life due to transient inhibition of mTORC1, which governs postnatal β-cell growth and differentiation. Importantly, restoration of mTORC1 activity in neonate β-cells was sufficient to rescue postnatal β-cell growth, and to improve diabetes. We propose a scenario for the development of permanent neonatal diabetes, possibly also common forms of diabetes, where early-life events inducing ER stress affect β-cell mass expansion due to mTOR inhibition.

    1. Stem Cells and Regenerative Medicine

    Insulin: Folding mutations suppress early beta-cell proliferation

    Honey Modi, James D Johnson
    Insight

    Exploring how proliferation and maturation of beta-cells can be impaired after birth will shed light on the origins of various forms of diabetes.

    1. Stem Cells and Regenerative Medicine

    Ecdysone steroid hormone remote controls intestinal stem cell fate decisions via the PPARγ-homolog Eip75B in Drosophila

    Lisa Zipper et al.
    Research Article

    Developmental studies revealed fundamental principles on how organ size and function is achieved, but less is known about organ adaptation to new physiological demands. In fruit flies, juvenile hormone (JH) induces intestinal stem cell (ISC) driven absorptive epithelial expansion balancing energy uptake with increased energy demands of pregnancy. Here, we show 20-Hydroxy-Ecdysone (20HE)-signaling controlling organ homeostasis with physiological and pathological implications. Upon mating, 20HE titer in ovaries and hemolymph are increased and act on nearby midgut progenitors inducing Ecdysone-induced-protein-75B (Eip75B). Strikingly, the PPARγ-homologue Eip75B drives ISC daughter cells towards absorptive enterocyte lineage ensuring epithelial growth. To our knowledge, this is the first time a systemic hormone is shown to direct local stem cell fate decisions. Given the protective, but mechanistically unclear role of steroid hormones in female colorectal cancer patients, our findings suggest a tumor-suppressive role for steroidal signaling by promoting postmitotic fate when local signaling is deteriorated.